R.A. Assal

899 total citations
36 papers, 597 citations indexed

About

R.A. Assal is a scholar working on Molecular Biology, Cancer Research and Immunology. According to data from OpenAlex, R.A. Assal has authored 36 papers receiving a total of 597 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 21 papers in Cancer Research and 8 papers in Immunology. Recurrent topics in R.A. Assal's work include MicroRNA in disease regulation (14 papers), Cancer-related molecular mechanisms research (13 papers) and Circular RNAs in diseases (6 papers). R.A. Assal is often cited by papers focused on MicroRNA in disease regulation (14 papers), Cancer-related molecular mechanisms research (13 papers) and Circular RNAs in diseases (6 papers). R.A. Assal collaborates with scholars based in Egypt, Saudi Arabia and Germany. R.A. Assal's co-authors include R.A. Youness, Mohamed Z. Gad, Amira Abdel Motaal, Ahmed Ihab Abdelaziz, Gamal Esmat, H.M. El Tayebi, Karim Adel Hosny, Hafez M. Hafez, Shahira M. Ezzat and Hesham I. El‐Askary and has published in prestigious journals such as Journal of Hepatology, Annals of Oncology and Frontiers in Immunology.

In The Last Decade

R.A. Assal

34 papers receiving 588 citations

Peers

R.A. Assal

IMMUN

ONCOL

BIOCH

Xuxiao He China

Lihua Dong China

Eun-Yeong Kim South Korea

Chaoliang Liao China

Antonio Strillacci Italy

Jeffrey D. Altenburg United States

Jiaqin Wu China

Fengjun Cao China

Xuxiao He China

R.A. Assal

289 ×0.7

211 ×0.5

112 ×1.0

IMMUN

71 ×1.1

ONCOL

20 ×0.4

BIOCH

Citations per year, relative to R.A. Assal R.A. Assal (= 1×) peers Xuxiao He

Countries citing papers authored by R.A. Assal

Since Specialization

Citations

This map shows the geographic impact of R.A. Assal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R.A. Assal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R.A. Assal more than expected).

Fields of papers citing papers by R.A. Assal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R.A. Assal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R.A. Assal. The network helps show where R.A. Assal may publish in the future.

Co-authorship network of co-authors of R.A. Assal

This figure shows the co-authorship network connecting the top 25 collaborators of R.A. Assal. A scholar is included among the top collaborators of R.A. Assal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R.A. Assal. R.A. Assal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Assal, R.A., et al.. (2026). Urolithin A counteracts cyclophosphamide-induced chemobrain in rats through modulation of mitochondrial signaling pathways. Journal of Ethnopharmacology. 361. 121312–121312.

Youness, R.A., et al.. (2025). Macrophage migration inhibitory factor (MIF) and the tumor ecosystem: a tale of inflammation, immune escape, and tumor growth. Frontiers in Immunology. 16. 1636839–1636839.

Assal, R.A., R.A. Youness, Karim Adel Hosny, et al.. (2024). OncomiR-181a promotes carcinogenesis by repressing the extracellular matrix proteoglycan decorin in hepatocellular carcinoma. BMC Gastroenterology. 24(1). 337–337. 2 indexed citations

Awaji, Aeshah A., et al.. (2024). Harnessing the supremacy of MEG3 LncRNA to defeat gastrointestinal malignancies. Pathology - Research and Practice. 256. 155223–155223. 8 indexed citations

Assal, R.A., Noha Mousaad Elemam, Asmaa Gomaa, et al.. (2024). A Novel Epigenetic Strategy to Concurrently Block Immune Checkpoints PD-1/PD-L1 and CD155/TIGIT in Hepatocellular Carcinoma. Translational Oncology. 45. 101961–101961. 18 indexed citations

Berger, Martin R., et al.. (2024). N‐[4‐(Benzyloxy)‐3‐methoxybenzyl)]adamantane‐1‐amine (DZH2), a dual CCR5 and CXCR4 inhibitor as a potential agent against triple negative breast cancer. Archiv der Pharmazie. 358(1). e2400146–e2400146. 1 indexed citations

Abdelhamid, A. M., et al.. (2024). miR-17–5p/STAT3/H19: A novel regulatory axis tuning ULBP2 expression in young breast cancer patients. Pathology - Research and Practice. 263. 155638–155638. 6 indexed citations

Motaal, Amira Abdel, et al.. (2020). 59P Hesperitin halts metastatic breast cancer through tweaking the interplay between the tumour suppressor miR-486-5p and the oncogenic lncRNA H19. Annals of Oncology. 31. S1235–S1235. 1 indexed citations

Assal, R.A., Karim Adel Hosny, H.M. El Tayebi, et al.. (2019). Methylation in MIRLET7A3 Gene Induces the Expression of IGF-II and Its mRNA Binding Proteins IGF2BP-2 and 3 in Hepatocellular Carcinoma. Frontiers in Physiology. 9. 1918–1918. 18 indexed citations

10.

Hanafi, Rasha S., et al.. (2019). The association of megalin and cubilin genetic variants with serum levels of 25-hydroxvitamin D and the incidence of acute coronary syndrome in Egyptians: A case control study. Journal of Advanced Research. 21. 49–56. 11 indexed citations

11.

Youness, R.A., et al.. (2019). Structural diversity of the cardenolide calotropin renders it as a targeted therapy for harnessing TNBC progression through tuning nitric oxide (NO) levels. Annals of Oncology. 30. i14–i14. 1 indexed citations

12.

Youness, R.A., R.A. Assal, Amira Abdel Motaal, & Mohamed Z. Gad. (2018). A novel role of sONE/NOS3/NO signaling cascade in mediating hydrogen sulphide bilateral effects on triple negative breast cancer progression. Nitric Oxide. 80. 12–23. 58 indexed citations

13.

Youness, R.A., et al.. (2017). Dual targeting of cystathionine β-synthase (CBS) and cystathionine γ-lyase (CSE) by miR-4317 displays a synergistic efficacy in repressing breast cancer progression. Annals of Oncology. 28. v584–v584. 3 indexed citations

14.

Youness, R.A., et al.. (2017). miR-4317, a novel tumor suppressor miRNA, alleviates immune-suppressive microenvironment induced by breast cancer. Annals of Oncology. 28. xi23–xi23. 1 indexed citations

15.

Youness, R.A., et al.. (2017). Down-regulated miR-486-5p acts as a tumor suppressor in breast cancer patients by targeting the metastatic mediator ICAM-1. Annals of Oncology. 28. xi22–xi22. 2 indexed citations

16.

Handoussa, Heba, R.A. Youness, R.A. Assal, et al.. (2017). Destabilizing the interplay between miR-1275 and IGF2BPs by Tamarix articulata and quercetin in hepatocellular carcinoma. Natural Product Research. 32(18). 2217–2220. 54 indexed citations

17.

Assal, R.A., et al.. (2016). miR-34a: Multiple Opposing Targets and One Destiny in Hepatocellular Carcinoma. Journal of Clinical and Translational Hepatology. 4(4). 300–305. 5 indexed citations

18.

Youness, R.A., et al.. (2016). MicroRNA-486-5p enhances hepatocellular carcinoma tumor suppression through repression of IGF-1R and its downstream mTOR, STAT3 and c-Myc. Oncology Letters. 12(4). 2567–2573. 72 indexed citations

19.

Tayebi, H.M. El, et al.. (2015). Transcriptional activation of the IGF-II/IGF-1R axis and inhibition of IGFBP-3 by miR-155 in hepatocellular carcinoma. Oncology Letters. 10(5). 3206–3212. 23 indexed citations

20.

Assal, R.A., et al.. (2012). A pleiotropic effect of the single clustered hepatic metastamiRs miR-96-5p and miR-182-5p on insulin-like growth factor II, insulin-like growth factor-1 receptor and insulin-like growth factor-binding protein-3 in hepatocellular carcinoma. Molecular Medicine Reports. 12(1). 645–650. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xuxiao He Breakdown of academic impact, for papers by Lihua Dong Breakdown of academic impact, for papers by Eun-Yeong Kim Breakdown of academic impact, for papers by Chaoliang Liao Breakdown of academic impact, for papers by Antonio Strillacci Breakdown of academic impact, for papers by Jeffrey D. Altenburg Breakdown of academic impact, for papers by Jiaqin Wu Breakdown of academic impact, for papers by Fengjun Cao